Pancreatic Cancer Early Detection Consortium

PRECEDE Study

The purpose of the Consortium is to provide a platform for sharing information about individuals that express high risk criteria for developing pancreas cancer. The Consortium is composed of 35 global academic centers that standardize data and sample collection to provide comprehensive risk modeling and align participants with the most appropriate resources. The collaboration with these international partners aims to improve the long-term survival of patients at increased risk for pancreas cancer.

Study Population
Individuals at elevated risk for developing pancreas cancer ages 18-90

Eligibility Criteria

- Hereditary Pancreatitis 40+ years old or
- Peutz-Jeghers Syndrome (STK11) 35+ years old or
- Strong family history of pancreas cancer on one side of the family tree or
- Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, ATM, BRCA1, HNPCC, PRSS1/2, MLH1, MSH2, MSH6, PMS2, EPCAM, or CTRC) with a first/second degree relative with PDAC 50+ years old
- Endoscopic evaluation of pancreas and appropriate imaging
- Willingness to have blood collected during clinic visit

Principle Investigator: Dr. James Farrell
Contact: Scott Merenda, BSN (203) 785-7019, scott.merenda@yale.edu